The power of genetic association analyses can be increased by jointly meta-analyzing multiple correlated phenotypes. Here, we develop a meta-analysis framework, Meta-MultiSKAT, that uses summary statistics to test for association between multiple continuous phenotypes and variants in a region of interest. Our approach models the heterogeneity of effects between studies through a kernel matrix and performs a variance component test for association. Using a genotype kernel, our approach can test for rare-variants and the combined effects of both common and rare-variants. To achieve robust power, within Meta-MultiSKAT, we developed fast and accurate omnibus tests combining different models of genetic effects, functional genomic annotations, multiple correlated phenotypes and heterogeneity across studies. Additionally, Meta-MultiSKAT accommodates situations where studies do not share exactly the same set of phenotypes or have differing correlation patterns among the phenotypes. Simulation studies confirm that Meta-MultiSKAT can maintain type-I error rate at exome-wide level of 2.5x10 -6 .
Introduction
The advent of large scale genome-wide association studies (GWAS) has shown that many distinct phenotypes share substantial genetic etiology (Bulik-Sullivan et al., 2015) and many loci have pleiotropic effects (Cotsapas et al., 2011; Purcell, Smoller, Cotsapas, Solovieff, & Lee, 2013; Sivakumaran et al., 2011) . To leverage the widespread pleiotropy, a statistical model to jointly test multiple phenotypes is beneficial. Although data on multiple related phenotypes are often collected in hospital or population based studies, association tests are usually performed with one phenotype at a time. Such methods that do not account for the correlation between phenotypes may lack power to detect cross-phenotype effects of associated loci (Ferreira & Purcell, 2009; Huang, Johnson, & O'Donnell, 2011; Ray, Pankow, & Basu, 2016) . Alternatively, joint tests which aggregate association signals in multiple phenotypes can substantially improve power over single phenotype-based tests (Ferreira & Purcell, 2009; Ray et al., 2016; Ried et al., 2012; Zhou & Stephens, 2014) . Meta-analysis of multiple studies, using association summary statistics, is a practical approach to increase power by increasing sample sizes (Panagiotou, Willer, Hirschhorn, & Ioannidis, 2013) . Meta-analysis is especially valuable for association analysis of variation on the lower end of the allele frequency spectrum, since detecting such associations often require large sample sizes. It seems logical to expect that meta-analyzing multiple phenotypes can further increase power of rare variant tests. Various methods have been developed for meta-analysis of multiple phenotypes (Majumdar, Haldar, Bhattacharya, & Witte, 2018; Ray & Boehnke, 2018; Zhu et al., 2015) , but most of them are single variant-based methods, which have low power to identify rare variant associations. More powerful gene or region-based tests for multiple phenotypes have been developed for use within a single study (Broadaway et al., 2016; Selyeong Lee et al., 2017; B. Wu & Pankow, 2016) . However, to the best of our knowledge, no work has been done to extend these methods to meta-analysis. This is partly because most of the methods are similarity-based non-parametric methods, which are difficult to extend to meta-analysis. We have developed a regression-based method, Multiple phenotype sequence kernel association test (Multi-SKAT) (Dutta, Scott, Boehnke, & Lee, 2019) , that can aggregate signals across models with different kernels, which cannot be done by current methods.
In this article we propose Meta-MultiSKAT, a meta-analysis extension of Multi-SKAT, which uses summary statistics. Meta-MultiSKAT models the relationship between effect sizes of different studies through a kernel matrix and performs a variance component test of association.
Our method is based on summary statistics from individual studies and retains useful features of Multi-SKAT, including fast computation. Meta-MultiSKAT can incorporate various missing data scenarios, including situations where studies do not share exactly the same set of phenotypes, and test for only rare variants as well as for the combined effects of both common and rare variants. The latter allows us to evaluate the overall effect of gene or region on multiple phenotypes. By using kinship adjusted score statistics, Meta-MultiSKAT can account for sample relatedness, an important feature to use in a study with widespread relatedness, such as the SardiNIA study (Sidore et al., 2015; Vacca et al., 2006) . To avoid loss of the power due to model misspecification, we have also developed a minimum p-value-based omnibus test that can aggregate results across different patterns of association. We evaluate the performance of our method through extensive type-I error and power simulations.
We applied Meta-MultiSKAT to meta-analyze four white blood cell (WBC) subtype traits from the Michigan Genomics Initiative (MGI) (Fritsche et al., 2018 ) study and the SardiNIA study (Sidore et al., 2015; Vacca et al., 2006) . In addition to detecting the genes PRG2 [MIM: 605601] and RP11-872D17.8, that had significant association signals with WBCs within one of the studies, Meta-MultiSKAT further identified two additionally associated genes (IRF8 [MIM: 601565] and CCL24 [MIM: 602495] ) that did not have any significant signals in either of the studies but were identified as significant only as a result of meta-analysis.
Material and Methods

Gene-based tests with multiple phenotypes for a single study
Suppose we intend to conduct a meta-analysis with S studies each having K phenotypes. For the s th study n s subjects are genotyped in a region that has m s variants. Let 
Under the null hypothesis,
is the phenotypeadjusted variant relationship matrix GAMuT(Broadaway et al., 2016) , MSKAT(B. Wu & Pankow, 2016) and DKAT(Zhan et al., 2017) . 
Input summary statistics from each study for meta-analysis
Meta-MultiSKAT: Meta-analysis of gene-based tests with multiple phenotypes
For simplicity, here we assume that all variants and phenotypes are observed in all S studies, so that m = m 1 =…= m s . We will relax this assumption later. Suppose summary statistics
are provided by S studies. We first construct the meta-score-vector as
follows a mixture of chi-square and the corresponding p-value can be obtained by inverting the characteristic function (See Appendix A for details).
Here we have introduced another kernel , which assumes that across the S studies the effects of the variants on all the phenotypes are the same (homogeneous). 
where , we use study specific weights obtained using MAF's of each study. Alternatively, functional scores, such as CADD (Kircher et al., 2014) and Eigen (Ionita-Laza, Capanu, De Rubeis, McCallum, & Buxbaum, 2014) can be used to upweight functionally important variants. In addition to using the MAF-based weighting, we have also explored the use of CADD scores as weights for variants in the meta-analysis of MGI and SardiNIA datasets.
Combined effect of common and rare variants (Meta-MultiSKAT-Common-Rare)
The default setting for SKAT type tests (SKAT, MultiSKAT and Meta-MultiSKAT) is to use a MAF-based weighting scheme that up-weights the contribution of the rare variants and down- 
The minimum p-value across these four tests will be used as the test statistic to evaluate the associations. 
Simulations
We carried out extensive simulation studies to evaluate the type I error rate and power of MetaMultiSKAT tests. For type-I error simulations and all power simulations, we generated 10,000 chromosomes over 1Mb-regions using a coalescent simulator with a European ancestry model (Schaffner,Stephen F et al., 2005) . Because the average total exon length of a gene is about 3 kbps, we randomly selected a 3 kb region for each simulated dataset to test for associations.
Simulation setting within individual study:
In the s th study, we generate K phenotypes according to the linear model:
is the covariance of the non-systematic error term. We use For estimating type-1 error rates we set
for all the variants in all the studies. For power simulation, we used two different settings. In the first setting, to estimate the power of MetaMultiSKAT as a rare-variant test, we set 30% of the rare variants (MAF ≤ 1%) to be causal.
Next, to estimate the performance of Meta-MultiSKAT as a test of combined effects of common and rare variants, we set 30% of all variants (common or rare) in the region to be causal. We modeled rare variants to have stronger association with the phenotypes than the common variants by setting
for all the simulation scenarios. For both the settings, as mentioned earlier, the first three among the five phenotypes in each study were associated with the region of interest.
Simulation settings across studies:
Throughout our simulations we have used settings which consist of three studies on European Data on four WBC subtypes percentages were included in the analysis: lymphocyte, monocyte, basophil and eosinophil. We excluded the data on percentage of neutrophils since it was highly correlated with lymphocytes (absolute value of correlation > 0.9 in both MGI and SardiNIA).
European samples with at most two phenotypes missing were included in the analysis for each of the studies. In all, we included 11,049 and 5,899 samples from the MGI and the SardiNIA studies, respectively (Table 1) .
We annotated protein-coding variants and a region of 20kb (± 10kb) around them to genes using Variant Effect Predictor (McLaren et al., 2016) software.
Within each study, we included age, sex, and study specific top four principal components (PC)
as fixed effect covariates in the analysis. In each study each of the four WBC subtypes were adjusted for the corresponding covariates and the residuals were quantile-normalized. Further, we estimated the kinship between the subjects in each study using KING (Manichaikul et al., 2010) and estimated the co-heritability matrix of the phenotypes using PHENIX (Dahl et al., 2016) . The inverse normalized residuals were then used in region-based multiple phenotype analysis (Multi-SKAT with kinship correction). The required summary statistics were calculated from the individual tests.
We conducted three sets of analysis with the extracted summary statistics. First to test the rarevariant associations of the phenotypes, we used Meta-MultiSKAT tests (Meta-Het, Met-Hom and Meta-Com) to test groups of protein-coding variants with pooled MAF ≤ 1%. We only included the groups that had at least three variants and a total minor allele count of 5. We used a Beta(1,25) weighting scheme to upweight the effect of the rare variants. Next, to test the combined effect of common and rare variants, we used the Meta-MultiSKAT-Common-Rare versions of the above tests with groups of protein-coding variants without any MAF cutoff. This means both common (MAF > 1%) and rare variants (MAF ≤ 1%) were present in the regions tested. For the rare variants we used Beta(1,25) weights and for the common variants we used Beta(0.5,0.5) weights (see Methods). Further, we annotated CADD scores for all the variants (common and rare) using ANNOVAR (Wang, Li, & Hakonarson, 2010) . We used these scores as weights in the genotype kernel ߑ ீ and performed the above Meta-MultiSKAT tests.
Results
Type-I error
For type-I error simulations, we simulated 10 7 independent datasets with three studies each having five phenotypes with a compound symmetric null residual covariance structure with offdiagonal elements being equal to 0.5, i.e. Type-I error rates were well maintained at all α levels. For example, at α = 2.5ൈ10 -6 , the largest estimated type-I error rate for any of the Meta-MultiSKAT tests was 2.7ൈ10 -6 , which was well within the estimated 95% confidence interval (Table 2) .
Power
We compared the empirical power of Meta-MultiSKAT tests with two possible existing approaches: minimum of the single phenotype MetaSKAT p-values (MinPhen-Hom and MinPhen-Het). For each simulation setting, we generated 1000 datasets and estimated the empirical power as the proportion of p-values less than 2.5ൈ10 -6 , reflecting the Bonferroni correction for testing 20,000 independent genes.
In power simulations, the first scenario considered the case that each study has the same set of causal variants and all of them are trait-increasing. Meta-Hom and Meta-Com had the highest powers in all scenarios while the power for Meta-Het is lower ( Figure 1 ). Also, there was a slight overall decrease in power from scenario A through scenario C. We expect this decrease in power since there is an increase of the amount of missing-ness in the scenarios A through C, though the power decrease is small (maximum relative decrease in empirical power < 1%).
Overall power of all the methods was higher when the correlation is high (ρ = 0.7).
Next, we considered a heterogeneous situation in which causal variants for each study were randomly selected so only small percentage of causal variants were shared among studies ( Figure 2 ). As expected, Meta-Het and Meta-Com had high power among the tests being compared. Meta-Hom was underpowered compared to these tests, while MinPhen-Hom and MinPhen-Het had lower power than the rest.
We then assumed that the causal variants for each study are chosen randomly within the region and 20% of the variants are trait-decreasing (80% are trait increasing) ( Figure 3 ). Similar to the previous scenario, Meta-Het and Meta-Com had higher power than the rest of the tests.
MinPhen-Hom and MinPhen-Het had lower power of detecting association signals, and MetaHom consistently had the lowest power across all the settings.
Next we considered a situation where the correlation structure among the phenotypes across studies varies. For the 1 st and 2 nd study the correlation among the 5 phenotypes is high (ρ = 0.7)
while for the 3 rd study, the correlation among the 5 phenotypes is moderate (ρ = 0.5). Similar to the previous cases, Meta-Het and Meta-Com maintained higher power than the rest of the tests ( Figure 4 ). As before, Meta-Hom performed poorly when 20% of the causal variants are traitdecreasing.
We further estimated type-1 error and power for the Meta-MultiSKAT-Common-Rare versions of the tests. The results are shown in Supplemental Table S3 , Supplemental Figure S2 and S3.
Type-I error was well maintained at different levels and the patterns of estimated power remained the same.
Overall our simulations show that Meta-MultiSKAT tests can improve power over the existing single phenotype-based meta-analysis approaches, while controlling type-I error rates. In particular, Meta-Com maintains robust power across all the scenarios regardless of the underlying genetic model.
Meta-analysis of WBC subtype traits
White blood cells (WBCs) are major cellular components of the human immune system. They et al., 2013; Kanai et al., 2018; Keller et al., 2014) . In this analysis, we tested the abundances of lymphocyte, monocyte, basophil and eosinophil. Correlations among the phenotypes are shown in Supplemental Figure S4 . There are more strong correlations in MGI samples.
We applied Meta-MultiSKAT tests to the analysis of WBC subtypes from the MGI and SardiNIA studies (See Methods for details). In particular, we applied Meta-Het, Meta-Hom and Meta-Com tests along with MinPhen-Hom and MinPhen-Het. We also evaluated the single-phenotype tests and multiple-phenotype tests (Multi-SKAT) for each study (Supplemental Table S1 ).
Results for rare variants with MAF-based weighting. First, we used the MAF-based weighting scheme to upweight the rare variants as suggested by Wu et al (MC et al., 2011) . Using the variants with pooled MAF ≤ 1%, we used Beta(1,25) weights. Overall 5,109 genes with at least 3 variants and a total minor allele count > 5 were tested. This produces a Bonferroni cut-off of
The QQ-plots shown in Figure 5 corresponding to the Meta-MultiSKAT tests do not show any indication of inflation (genomic control varying from 0.998 to 1.003). Table 3 Table S2 ) show that Meta-MultiSKAT has a robust power under such scenarios while controlling type-1 error.
Computation Time
We estimated the computation time of Meta-MultiSKAT tests using simulated datasets on 3 studies (as described in the Simulations section) with 5 phenotypes and 50 genetic variants. We set the number of perturbation iterations to 1000. On average, Meta-Hom and Meta-Het tests required approximately 8 CPU-seconds (Intel Xeon 2.80 GHz) and Meta-Com required 12 CPUsec. Analyzing the MGI and SardiNIA datasets, using the extracted summary statistics from each study, required about thirty CPU-hours when parallelized to 10 processes.
Discussion
We propose a new method, Meta-MultiSKAT, which meta-analyzes region-based association of multiple phenotypes across studies. The model is based on study-specific summary statistics for the region and is flexible to accommodate a range of heterogeneity of genetic effects across studies. The simulation and the real data analysis results involving the summary statistics from MGI and SardiNIA demonstrate that Meta-MultiSKAT can substantially increase power compared to the existing tests and can identify additional association signals, while maintaining the desired type-I error rate. The method is implemented as an R-package (MetaMultiSKAT, see Web Resources).
We note that the test statistics, assuming homogeneous genetic effects, are essentially identical to joint analysis test statistics using all individual level data and accounting for study-specific covariate effects, resulting in nearly identical power using meta-analysis and joint analysis. Our power-simulations confirm this finding (Supplemental Figure S1 ). The asymptotic p-value calculations for Meta-MultiSKAT rely on the normality assumption of the score vectors. When at least one pair of the phenotypes is very strongly correlated (i.e. absolute correlation > 0.9), this assumption may be violated. Currently, we do not have a mechanism to adaptively select an active set of phenotypes which might produce the optimal association signal for a particular region. Hence, we recommend that the data be pre-pruned for correlation and such strongly correlated phenotypes be excluded before analysis.
Currently, the framework of Meta-MultiSKAT is developed for continuous phenotypes. A direction of future research is to extend this framework for phenotypes that are a mixture of continuous and discrete types.
In summary, we have developed Meta-MultiSKAT, a meta-analysis method for testing rarevariant associations of multiple correlated phenotypes. Meta-MultiSKAT has robust power and can handle practical problems such as missing data and different covariance structures. The method provides a scalable and practical solution to test multiple phenotypes jointly and thus can contribute to detecting regions in the genome with pleiotropic effects. p-values obtained from MGI-SardiNIA meta-analysis.
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